The ordinary s NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape ...
Hosted on MSN1mon
SLXN stock touches 52-week low at $0.82 amid sharp annual declineI n a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...
Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...
Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...
Silexion Therapeutics (SLXN) announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered ...
(RTTNews) - Silexion Therapeutics (SLXN) announced positive data from preclinical studies of SIL204, its RNA interference (RNAi) therapy, in orthotopic pancreatic cancer models. These findings ...
Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback